ABBOTT LABORATORIES (ABL.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ABL - US0028241000 - Common Stock
110.34 EUR
+2.38 (+2.2%)
Taking everything into account, ABL scores 7 out of 10 in our fundamental rating. ABL was compared to 60 industry peers in the Health Care Equipment & Supplies industry. ABL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ABL has a decent growth rate and is not valued too expensively. This makes ABL very considerable for quality investing!
1. Profitability
1.1 Basic Checks
ABL had positive earnings in the past year.
In the past year ABL had a positive cash flow from operations.
Each year in the past 5 years ABL has been profitable.
ABL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ABL has a Return On Assets of 16.60%. This is amongst the best in the industry. ABL outperforms 93.33% of its industry peers.
ABL has a Return On Equity of 27.43%. This is amongst the best in the industry. ABL outperforms 95.00% of its industry peers.
ABL's Return On Invested Capital of 9.90% is amongst the best of the industry. ABL outperforms 81.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABL is in line with the industry average of 8.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROIC | 9.9% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
1.3 Margins
With an excellent Profit Margin value of 31.88%, ABL belongs to the best of the industry, outperforming 98.33% of the companies in the same industry.
In the last couple of years the Profit Margin of ABL has grown nicely.
ABL has a Operating Margin of 18.29%. This is in the better half of the industry: ABL outperforms 78.33% of its industry peers.
ABL's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 56.19%, ABL is in line with its industry, outperforming 53.33% of the companies in the same industry.
In the last couple of years the Gross Margin of ABL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% |
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ABL is still creating some value.
Compared to 1 year ago, ABL has about the same amount of shares outstanding.
The number of shares outstanding for ABL has been reduced compared to 5 years ago.
ABL has a better debt/assets ratio than last year.
2.2 Solvency
ABL has an Altman-Z score of 5.70. This indicates that ABL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.70, ABL belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
ABL has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
ABL has a Debt to FCF ratio of 1.87. This is amongst the best in the industry. ABL outperforms 81.67% of its industry peers.
ABL has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
ABL's Debt to Equity ratio of 0.23 is fine compared to the rest of the industry. ABL outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 5.7 |
ROIC/WACC1.19
WACC8.34%
2.3 Liquidity
ABL has a Current Ratio of 1.70. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
ABL has a Current ratio (1.70) which is in line with its industry peers.
ABL has a Quick Ratio of 1.24. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
ABL has a Quick ratio (1.24) which is in line with its industry peers.
ABL does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
ABL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.40%, which is quite good.
Measured over the past 5 years, ABL shows a small growth in Earnings Per Share. The EPS has been growing by 7.59% on average per year.
Looking at the last year, ABL shows a small growth in Revenue. The Revenue has grown by 6.37% in the last year.
The Revenue has been growing slightly by 5.63% on average over the past years.
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
3.2 Future
ABL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.09% yearly.
Based on estimates for the next years, ABL will show a small growth in Revenue. The Revenue will grow by 7.12% on average per year.
EPS Next Y11.45%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
EPS Next 5Y10.09%
Revenue Next Year6.43%
Revenue Next 2Y7.06%
Revenue Next 3Y7.17%
Revenue Next 5Y7.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ABL is valuated quite expensively with a Price/Earnings ratio of 25.48.
Based on the Price/Earnings ratio, ABL is valued a bit cheaper than 66.67% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.45. ABL is around the same levels.
With a Price/Forward Earnings ratio of 22.16, ABL is valued on the expensive side.
ABL's Price/Forward Earnings ratio is in line with the industry average.
ABL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.48 | ||
| Fwd PE | 22.16 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ABL is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, ABL is valued a bit cheaper than the industry average as 63.33% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.97 | ||
| EV/EBITDA | 19.85 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.23
PEG (5Y)3.36
EPS Next 2Y10.79%
EPS Next 3Y10.83%
5. Dividend
5.1 Amount
ABL has a Yearly Dividend Yield of 1.90%. Purely for dividend investing, there may be better candidates out there.
ABL's Dividend Yield is a higher than the industry average which is at 2.16.
ABL's Dividend Yield is slightly below the S&P500 average, which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.9% |
5.2 History
On average, the dividend of ABL grows each year by 11.40%, which is quite nice.
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
28.93% of the earnings are spent on dividend by ABL. This is a low number and sustainable payout ratio.
ABL's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
FRA:ABL (11/21/2025, 7:00:00 PM)
110.34
+2.38 (+2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners80.68%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap192.04B
Revenue(TTM)43.84B
Net Income(TTM)13.98B
Analysts78.89
Price Target125.57 (13.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.9% |
Yearly Dividend1.92
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)2.63%
PT rev (3m)1.82%
EPS NQ rev (1m)0.27%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.48 | ||
| Fwd PE | 22.16 | ||
| P/S | 5.04 | ||
| P/FCF | 31.97 | ||
| P/OCF | 24.25 | ||
| P/B | 4.34 | ||
| P/tB | 10.34 | ||
| EV/EBITDA | 19.85 |
EPS(TTM)4.33
EY3.92%
EPS(NY)4.98
Fwd EY4.51%
FCF(TTM)3.45
FCFY3.13%
OCF(TTM)4.55
OCFY4.12%
SpS21.88
BVpS25.43
TBVpS10.67
PEG (NY)2.23
PEG (5Y)3.36
Graham Number49.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROCE | 11.52% | ||
| ROIC | 9.9% | ||
| ROICexc | 11.13% | ||
| ROICexgc | 21.33% | ||
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% | ||
| FCFM | 15.78% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
ROICexc(3y)12.18%
ROICexc(5y)11.89%
ROICexgc(3y)32.65%
ROICexgc(5y)35.03%
ROCE(3y)12.16%
ROCE(5y)11.86%
ROICexgc growth 3Y-24.08%
ROICexgc growth 5Y-8.19%
ROICexc growth 3Y-10.71%
ROICexc growth 5Y6.04%
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 81.77% | ||
| Profit Quality | 49.49% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 5.7 |
F-Score7
WACC8.34%
ROIC/WACC1.19
Cap/Depr(3y)63.63%
Cap/Depr(5y)61.92%
Cap/Sales(3y)4.94%
Cap/Sales(5y)5.1%
Profit Quality(3y)82.78%
Profit Quality(5y)99.6%
High Growth Momentum
Growth
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
EPS Next Y11.45%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
EPS Next 5Y10.09%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
Revenue Next Year6.43%
Revenue Next 2Y7.06%
Revenue Next 3Y7.17%
Revenue Next 5Y7.12%
EBIT growth 1Y15.18%
EBIT growth 3Y-6.62%
EBIT growth 5Y8.41%
EBIT Next Year27.77%
EBIT Next 3Y15.64%
EBIT Next 5Y12.85%
FCF growth 1Y53.98%
FCF growth 3Y-9.78%
FCF growth 5Y7.14%
OCF growth 1Y39.24%
OCF growth 3Y-6.69%
OCF growth 5Y6.88%
ABBOTT LABORATORIES / ABL.DE FAQ
What is the fundamental rating for ABL stock?
ChartMill assigns a fundamental rating of 7 / 10 to ABL.DE.
What is the valuation status for ABL stock?
ChartMill assigns a valuation rating of 4 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Fairly Valued.
What is the profitability of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of ABBOTT LABORATORIES (ABL.DE) stock?
The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 25.48 and the Price/Book (PB) ratio is 4.34.
Can you provide the financial health for ABL stock?
The financial health rating of ABBOTT LABORATORIES (ABL.DE) is 8 / 10.